Since obesity is a key feature in T2DM, studies demonstrate that changes in adipose tissue induce dysregulation in adipokines such as adiponectin and receptors involved in lipid metabolism such as Proliferator–activated receptor γ (PPAR-γ) (Bermudez et al., 2010). The gene discussed is ADIPOQ; the disease is Obesity.